By Suherman Candra Maholtra 
The landscape of hematologic oncology is witnessing a transformative shift as researchers pioneer a method to "cloak" healthy donor cells from the very treatments designed to eradicate cancer. For patients battling the most aggressive forms of blood cancer, such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), a stem cell transplant often represents the final frontier of curative intent. However, the high rate of relapse following transplantation frequently leaves clinicians with a dwindling arsenal of options. A landmark clinical trial led by the Washington University School of Medicine in St. Louis has now demonstrated that CRISPR-based gene editing of donor stem cells can create a protective "shield," allowing for the use of potent targeted therapies that would otherwise be too toxic for the patient’s bone marrow.
The findings, recently published in the journal Nature Medicine, detail a strategy that involves removing a specific protein, CD33, from donor stem cells before they are infused into the patient. By doing so, researchers have created a biological bypass: because the healthy, transplanted blood system no longer expresses CD33, subsequent therapies programmed to attack that protein can focus exclusively on the malignant cells while sparing the patient’s essential blood-forming infrastructure. This approach addresses one of the most significant hurdles in modern immunotherapy—the inability to distinguish between cancerous targets and the healthy cells required for survival.
The Challenge of Targeted Immunotherapy in Myeloid Cancers
In the realm of B-cell malignancies, such as certain lymphomas and leukemias, Chimeric Antigen Receptor T-cell (CAR-T) therapy has achieved revolutionary success. This success is largely due to the presence of markers like CD19, which are found on B-cells but not on the essential stem cells that replenish the blood system. While CAR-T therapy might deplete a patient’s B-cells, the body can survive without them through regular antibody infusions.
However, AML and MDS present a far more complex challenge. These cancers arise from the myeloid lineage—the same lineage that produces white blood cells, red blood cells, and platelets. The proteins most commonly found on AML cells, such as CD33, are also expressed on healthy myeloid progenitor cells. Consequently, if a doctor administers a CAR-T therapy or a potent antibody-drug conjugate (ADC) targeting CD33, the treatment will not only seek out the leukemia but also systematically destroy the patient’s entire blood-forming system. This "on-target, off-tumor" toxicity leads to prolonged, life-threatening bone marrow suppression, leaving patients vulnerable to catastrophic infections and hemorrhage.
According to Dr. John F. DiPersio, the Virginia E. & Sam J. Golman Professor of Medicine at WashU Medicine and the study’s corresponding author, this shared expression has effectively "locked" the door to using CAR-T therapies for AML. The trial’s objective was to unlock that door by modifying the donor cells so they no longer "look" like targets to the immune system.
A Chronology of Innovation: From Lab to Bedside
The conceptual framework for this strategy originated with Dr. Miriam Y. Kim, currently an assistant professor of medicine at WashU Medicine. Dr. Kim’s research began during her time as a postdoctoral fellow at the University of Pennsylvania, a hub for CAR-T development, and continued within Dr. DiPersio’s laboratory. The central hypothesis was elegant in its simplicity: if CD33 is not essential for the survival and function of healthy blood cells, removing it would provide a safe haven for the hematopoietic system during aggressive anti-cancer treatment.
To test this, researchers partnered with Vor Biopharma to develop "tremtelectogene empogeditemcel" (trem-cel), a product consisting of donor stem cells that have undergone CRISPR-Cas9 gene editing to delete the CD33 gene. The clinical trial, a Phase 1/2 multicenter study, was conducted across 15 sites in the United States and Canada, including the Siteman Cancer Center at Barnes-Jewish Hospital.
The trial enrolled 30 adult patients, all of whom suffered from high-risk AML or MDS and were candidates for allogeneic stem cell transplantation. The primary goals were to determine if these edited cells could successfully "engraft"—or take root in the bone marrow—and if they could function normally without the CD33 protein.
Analyzing the Trial Data: Engraftment and Safety
One of the most critical metrics in any stem cell transplant is the speed and stability of engraftment. If the gene-edited cells failed to produce a functioning blood system, the strategy would be non-viable. The results, however, were highly encouraging. All 30 patients achieved successful engraftment by day 28 post-transplant. On average, patients saw a return of platelet production by day 16, a timeline that mirrors traditional, non-edited stem cell transplants.
Once the new blood system was established, the researchers moved to the second phase of the trial: testing the "shield" against a CD33-targeted agent. For this, they used gemtuzumab ozogamicin, an FDA-approved antibody-drug conjugate that delivers a lethal dose of chemotherapy directly to CD33-positive cells. Under normal circumstances, gemtuzumab ozogamicin is known for causing severe drops in blood counts (cytopenias) and liver toxicity, which limits its use as a maintenance therapy after transplant.
In this study, 19 patients received escalating doses of gemtuzumab ozogamicin. Remarkably, these patients maintained their blood cell counts despite the presence of the drug. This provided definitive proof-of-concept that the CD33-deleted cells were indeed "invisible" to the drug, allowing the therapy to theoretically circulate and hunt for residual cancer cells without compromising the patient’s marrow.
The Human Impact: A Case Study in Remission
While the Phase 1/2 trial focused largely on safety and engraftment, a separate case study published in JCO Precision Oncology in October 2025 highlights the potential for long-term efficacy. Dr. DiPersio and his team reported on a patient with exceptionally high-risk AML who underwent a CD33-deleted transplant.
When the patient’s cancer inevitably returned, the medical team took the next step: administering CD33-targeted CAR-T cells. These CAR-T cells were engineered from the same donor who provided the original stem cells. Because the patient’s healthy blood system was now derived from the CD33-deleted trem-cel, the CAR-T cells were able to target the relapsed AML with surgical precision.
The patient achieved a complete remission and remained cancer-free for more than a year following the CAR-T infusion. Furthermore, tests confirmed that the patient’s entire blood system remained entirely CD33-negative, proving that the edited cells had permanently replaced the original marrow and were successfully performing all necessary biological functions.
Broader Implications for Oncology and Gene Editing
The success of the trem-cel trial carries profound implications for the future of oncology. By demonstrating that healthy tissues can be genetically modified to withstand targeted therapies, researchers have opened a new pathway for treating various solid tumors and blood cancers where shared antigens have previously made treatment too dangerous.
From a clinical perspective, this approach could redefine the "standard of care" for AML. Currently, the five-year survival rate for AML remains stubbornly low, particularly for older patients or those with high-risk genetic mutations. The ability to use CAR-T cells—which have been "living drugs" capable of providing long-term surveillance against cancer—could significantly reduce the high rates of relapse that currently plague the field.
Furthermore, the study reinforces the safety and utility of CRISPR-Cas9 in a clinical setting. While concerns regarding "off-target" effects of gene editing remain a topic of intense study, the stable engraftment and lack of unexpected toxicities in this trial provide a strong argument for the continued integration of gene editing in hematology.
Future Directions and Unresolved Questions
Despite the optimism, the medical community remains cautious. The study noted that the side effects observed—such as anemia, fever, and graft-versus-host disease (GVHD)—were consistent with standard transplants, but the mortality rate remains a reminder of the severity of these diseases. Of the 30 patients, seven passed away during the study period; four from cancer progression and three from transplant-related complications like sepsis and organ failure.
The next phase of research will likely focus on combining trem-cel with even more potent immunotherapies. While gemtuzumab ozogamicin served as an effective test, the ultimate goal is to pair these shielded transplants with next-generation CAR-T cells or bispecific T-cell engagers (BiTEs) that can provide a more robust and durable anti-leukemic effect.
Dr. DiPersio emphasized that the foundation has been laid. "We are hopeful we will be able to combine this with CD33-targeted immunotherapies… and improve treatment options for patients with these very aggressive blood cancers," he stated. The strategy represents a shift from simply trying to kill the cancer to re-engineering the host’s biology to survive the cure.
As the oncology community moves forward, the focus will expand to identifying other proteins that can be safely deleted from stem cells, potentially allowing for "multi-antigen" shielding. This would prevent the cancer from escaping treatment by simply downregulating a single protein like CD33. For now, the successful "cloaking" of donor cells stands as a landmark achievement in the quest to make the most powerful cancer treatments safe for the patients who need them most.
